vs
ANI PHARMACEUTICALS INC（ANIP）与Doximity, Inc.（DOCS）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是Doximity, Inc.的1.3倍（$247.1M vs $185.1M），Doximity, Inc.净利率更高（33.3% vs 11.1%，领先22.1%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 9.8%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 25.2%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
ANIP vs DOCS — 直观对比
营收规模更大
ANIP
是对方的1.3倍
$185.1M
营收增速更快
ANIP
高出19.9%
9.8%
净利率更高
DOCS
高出22.1%
11.1%
两年增速更快
ANIP
近两年复合增速
25.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $185.1M |
| 净利润 | $27.5M | $61.6M |
| 毛利率 | — | 89.9% |
| 营业利润率 | 14.1% | 38.9% |
| 净利率 | 11.1% | 33.3% |
| 营收同比 | 29.6% | 9.8% |
| 净利润同比 | 367.5% | -18.1% |
| 每股收益（稀释后） | $1.14 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPDOCS
| Q4 25 | $247.1M | $185.1M | ||
| Q3 25 | $227.8M | $168.5M | ||
| Q2 25 | $211.4M | $145.9M | ||
| Q1 25 | $197.1M | $138.3M | ||
| Q4 24 | $190.6M | $168.6M | ||
| Q3 24 | $148.3M | $136.8M | ||
| Q2 24 | $138.0M | $126.7M | ||
| Q1 24 | $137.4M | $118.1M |
净利润ANIPDOCS
| Q4 25 | $27.5M | $61.6M | ||
| Q3 25 | $26.6M | $62.1M | ||
| Q2 25 | $8.5M | $53.3M | ||
| Q1 25 | $15.7M | $62.5M | ||
| Q4 24 | $-10.3M | $75.2M | ||
| Q3 24 | $-24.2M | $44.2M | ||
| Q2 24 | $-2.3M | $41.4M | ||
| Q1 24 | $18.2M | $40.6M |
毛利率ANIPDOCS
| Q4 25 | — | 89.9% | ||
| Q3 25 | — | 90.3% | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | 89.5% | ||
| Q4 24 | — | 91.6% | ||
| Q3 24 | — | 90.0% | ||
| Q2 24 | — | 89.3% | ||
| Q1 24 | — | 89.4% |
营业利润率ANIPDOCS
| Q4 25 | 14.1% | 38.9% | ||
| Q3 25 | 15.9% | 37.8% | ||
| Q2 25 | 6.6% | 37.4% | ||
| Q1 25 | 13.3% | 35.2% | ||
| Q4 24 | -2.3% | 47.4% | ||
| Q3 24 | -13.8% | 38.8% | ||
| Q2 24 | 3.7% | 36.4% | ||
| Q1 24 | 14.8% | 35.5% |
净利率ANIPDOCS
| Q4 25 | 11.1% | 33.3% | ||
| Q3 25 | 11.7% | 36.8% | ||
| Q2 25 | 4.0% | 36.5% | ||
| Q1 25 | 8.0% | 45.2% | ||
| Q4 24 | -5.4% | 44.6% | ||
| Q3 24 | -16.3% | 32.3% | ||
| Q2 24 | -1.7% | 32.7% | ||
| Q1 24 | 13.2% | 34.4% |
每股收益（稀释后）ANIPDOCS
| Q4 25 | $1.14 | $0.31 | ||
| Q3 25 | $1.13 | $0.31 | ||
| Q2 25 | $0.36 | $0.27 | ||
| Q1 25 | $0.69 | $0.31 | ||
| Q4 24 | $-0.45 | $0.37 | ||
| Q3 24 | $-1.27 | $0.22 | ||
| Q2 24 | $-0.14 | $0.21 | ||
| Q1 24 | $0.82 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $64.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $979.3M |
| 总资产 | $1.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPDOCS
| Q4 25 | $285.6M | $64.8M | ||
| Q3 25 | $262.6M | $169.2M | ||
| Q2 25 | $217.8M | $137.3M | ||
| Q1 25 | $149.8M | $209.6M | ||
| Q4 24 | $144.9M | $165.3M | ||
| Q3 24 | $145.0M | $184.2M | ||
| Q2 24 | $240.1M | $111.4M | ||
| Q1 24 | $228.6M | $96.8M |
股东权益ANIPDOCS
| Q4 25 | $540.7M | $979.3M | ||
| Q3 25 | $505.8M | $1.1B | ||
| Q2 25 | $436.8M | $1.0B | ||
| Q1 25 | $418.6M | $1.1B | ||
| Q4 24 | $403.7M | $1.0B | ||
| Q3 24 | $405.9M | $961.2M | ||
| Q2 24 | $455.8M | $913.6M | ||
| Q1 24 | $452.0M | $901.4M |
总资产ANIPDOCS
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | 0.99× |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPDOCS
| Q4 25 | $30.4M | $60.9M | ||
| Q3 25 | $44.1M | $93.9M | ||
| Q2 25 | $75.8M | $62.1M | ||
| Q1 25 | $35.0M | $98.5M | ||
| Q4 24 | $15.9M | $65.2M | ||
| Q3 24 | $12.5M | $68.3M | ||
| Q2 24 | $17.4M | $41.2M | ||
| Q1 24 | $18.3M | $63.9M |
自由现金流ANIPDOCS
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPDOCS
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPDOCS
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 1.3% | 0.0% | ||
| Q3 24 | 3.2% | 0.0% | ||
| Q2 24 | 3.2% | 0.0% | ||
| Q1 24 | 3.3% | 0.0% |
现金转化率ANIPDOCS
| Q4 25 | 1.10× | 0.99× | ||
| Q3 25 | 1.66× | 1.51× | ||
| Q2 25 | 8.87× | 1.16× | ||
| Q1 25 | 2.23× | 1.58× | ||
| Q4 24 | — | 0.87× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | 1.00× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
